Table 1.
Skin exoerythrocytic stages do not give rise to blood-stage infection
| Expt no. | Parasite speciesa | Route of inoculation | Dose | PQb | No. of mice | No. positive for blood-stage parasites | Prepatent period (days)c |
|---|---|---|---|---|---|---|---|
| 1 | P. berghei | Intravenous | 4,000 sporozoites | + | 8 | 1 | 8.0 |
| Mosquito bite | 30 bites | + | 8 | 1 | 8.0 | ||
| Mosquito bite | 30 bites | − | 3 | 3 | 3.0 | ||
| 2 | P. berghei | Intravenous | 1,000 sporozoites | + | 4 | 0 | NA |
| Mosquito bite | 10 bites | + | 8 | 0 | NA | ||
| Mosquito bite | 10 bites | − | 3 | 3 | 4.5 | ||
| 3 | P. berghei | Intravenous | 1,000 sporozoites | + | 3 | 0 | NA |
| Mosquito bite | 10 bites | + | 8 | 0 | NA | ||
| Mosquito bite | 10 bites | − | 3 | 3 | 4.6 | ||
| 4 | P. yoelii | Mosquito bite | 15 bites | + | 10 | 0 | NA |
| Mosquito bite | 15 bites | − | 3 | 3 | 3 |
a
C57BL/6 mice were used for P. berghei experiments, and BALB/c mice were used for P. yoelli experiments.
b
PQ, primaquine. +, treated; −, untreated.
c
NA, not applicable, i.e., none of the mice became positive for blood-stage parasites.